{"nctId":"NCT01267227","briefTitle":"Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress","startDateStruct":{"date":"2010-12"},"conditions":["Hyperlipidemia","Blood Pressure","Oxidative Stress"],"count":80,"armGroups":[{"label":"High Dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pterostilbene 125 mg twice daily"]},{"label":"Low Dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pterostilbene 50 mg twice daily"]},{"label":"Low Dose Combination","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pterostilbene 50 mg twice daily","Drug: Grape Extract"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Pterostilbene 50 mg twice daily","otherNames":["pTeroPure"]},{"name":"Placebo","otherNames":[]},{"name":"Grape Extract","otherNames":["ShanStar Concord Grape"]},{"name":"Pterostilbene 125 mg twice daily","otherNames":["pTeropure"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients ≥18 years of age with a previous TC ≥200 mg/dL and/or a LDL ≥100 mg/dL on either no therapy or stable therapy\n* Any concomitant cholesterol medication (not listed in the exclusion criteria) must be at a stable dose for at least 2 months prior to baseline laboratory\n\nExclusion Criteria:\n\n* Patients with significant hepatic, renal or gastrointestinal tract disease\n* Receiving thiazolidinediones or fibric acid derivatives\n* Current overt cardiovascular disease\n* Women of reproductive potential not receiving birth control\n* Pregnant/nursing women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"88 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"LDL","description":"Increase in low density lipoprotein (LDL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.67","spread":null},{"groupId":"OG001","value":"20.04","spread":null},{"groupId":"OG002","value":"5.33","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Pressure","description":"Reduction in systolic blood pressure versus placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.77","spread":null},{"groupId":"OG001","value":"3.67","spread":null},{"groupId":"OG002","value":"6.72","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjective Adverse Effects","description":"Number of participants with adverse effects as a measure of safety","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["GI","Muscle Pain","Itching"]}}}